GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Valuation Rank

Voyager Therapeutics (STU:VT6) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Voyager Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (STU:VT6) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » Valuation Rank
Comparable Companies
AURA VIGL THRD JANX NAUT LXRX ABUS AVTE KALV FUSN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
VYGR:USA VT6:Germany
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Website
https://www.voyagertherapeutics.com
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.